ATE99172T1 - Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung. - Google Patents

Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.

Info

Publication number
ATE99172T1
ATE99172T1 AT89830491T AT89830491T ATE99172T1 AT E99172 T1 ATE99172 T1 AT E99172T1 AT 89830491 T AT89830491 T AT 89830491T AT 89830491 T AT89830491 T AT 89830491T AT E99172 T1 ATE99172 T1 AT E99172T1
Authority
AT
Austria
Prior art keywords
treatment
carnitine
acetyl
cataract
pharmaceutical compositions
Prior art date
Application number
AT89830491T
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE99172T1 publication Critical patent/ATE99172T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89830491T 1988-11-15 1989-11-13 Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung. ATE99172T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8848558A IT1235153B (it) 1988-11-15 1988-11-15 Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
EP89830491A EP0375628B1 (de) 1988-11-15 1989-11-13 Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung

Publications (1)

Publication Number Publication Date
ATE99172T1 true ATE99172T1 (de) 1994-01-15

Family

ID=11267312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89830491T ATE99172T1 (de) 1988-11-15 1989-11-13 Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.

Country Status (8)

Country Link
US (1) US5037851A (de)
EP (1) EP0375628B1 (de)
JP (1) JPH02180820A (de)
AT (1) ATE99172T1 (de)
DE (1) DE68911891T2 (de)
ES (1) ES2062100T3 (de)
IT (1) IT1235153B (de)
ZA (1) ZA898667B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
SI0951909T2 (sl) 1998-03-19 2010-11-30 Sigma Tau Ind Farmaceuti Kombinirana zmes ki vsebuje L karnitin ali alkanoil L karnitin glikozaminoglikan in ali njegov sestavni del
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
SK287787B6 (sk) * 2000-12-15 2011-09-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Použitie L-karnitínu ako stabilizačného činidla proteínov
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
JP5117384B2 (ja) * 2005-07-01 2013-01-16 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 点眼剤の形態における眼用生理学的サプリメントまたは医薬の調製のためのｌ−カルニチンまたはアルカノイルｌ−カルニチンの使用
AU2006268787B2 (en) 2005-07-08 2012-02-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of a combination comprising L-carnitine or alkanoyl L-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
EP2363126A1 (de) 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Zusammensetzung mit L-Carnitin als aktivem Bestandteil in Kombination mit hydroxykynurenine-O-beta-DL-glucoside,zur Verhinderung und/oder Behandlung von Augenkrankheiten, die aufgrund der ultravioletten Strahlung entstanden sind
US9114120B2 (en) 2010-11-22 2015-08-25 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Therapeutical method for the treatment of the Leber optic neuropathy
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP2783695A1 (de) 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Physiologische Ergänzung oder Medikament zur ophthalmischen Verwendung mit L-Carnitin oder Alkanoyl-L-Carnitinen in Kombination mit Eledoisin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock

Also Published As

Publication number Publication date
ZA898667B (en) 1990-10-31
DE68911891D1 (de) 1994-02-10
DE68911891T2 (de) 1994-04-21
IT1235153B (it) 1992-06-22
EP0375628A2 (de) 1990-06-27
IT8848558A0 (it) 1988-11-15
JPH02180820A (ja) 1990-07-13
US5037851A (en) 1991-08-06
ES2062100T3 (es) 1994-12-16
EP0375628A3 (de) 1991-08-14
EP0375628B1 (de) 1993-12-29

Similar Documents

Publication Publication Date Title
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
CA2004239A1 (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
DK0773020T3 (da) Farmaceutiske præparater indeholdende L-carnitin eller derivater deraf i kombination med resveratrol eller derivater deraf til forebyggelsen og behandlingen af cardiovaskulære lidelser, perifere vaskulære sygdomme og perifer diabetisk neuropati
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
KR970061244A (ko) 치매 치료용 약학 조성물
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
KR970025615A (ko) 암 전이 억제제
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
NO960347L (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
ATE123416T1 (de) Oral verabreichbares pharmazeutisches mittel, insbesondere zur eisen- und magnesiumsubstitutionstherapie.
ATE79750T1 (de) Pharmazeutische zusammensetzung mit antikrebswirkung und methode fuer die behandlung von krebs.
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
ATE323481T1 (de) Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.
SE8304818L (sv) Medicin med magsarslekande, spasmolytisk och lokalanesteserande verkan
ATE73326T1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.
TH19526A (th) วิธีการและสารผสมสำหรับรักษาโรคตับอักเสบชนิดออโตอิมมูน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee